<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
UNAUDITED   CONDENSED   CONSOLIDATED   FINANCIAL   STATEMENTS  INCLUDED  IN  THE
REGISTRANT'S  FORM 10-Q FOR THE PERIOD  ENDED JUNE 30, 2000 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FORM 10-Q.
</LEGEND>
<CIK>                         0001012270
<NAME>                        CollaGenex Pharmaceuticals, Inc.
<MULTIPLIER>                                   1,000
<CURRENCY>                                     U.S. Dollars

<S>                             <C>
<PERIOD-TYPE>                                  6-Mos
<FISCAL-YEAR-END>                              Dec-31-2000
<PERIOD-START>                                 Jan-01-2000
<PERIOD-END>                                   Jun-30-2000
<EXCHANGE-RATE>                                1
<CASH>                                         8,745
<SECURITIES>                                   2,081
<RECEIVABLES>                                  3,100
<ALLOWANCES>                                   401
<INVENTORY>                                    385
<CURRENT-ASSETS>                               14,691
<PP&E>                                         1,120
<DEPRECIATION>                                 380
<TOTAL-ASSETS>                                 15,458
<CURRENT-LIABILITIES>                          5,683
<BONDS>                                        0
                          0
                                    2
<COMMON>                                       87
<OTHER-SE>                                     9,604
<TOTAL-LIABILITY-AND-EQUITY>                   15,458
<SALES>                                        11,233
<TOTAL-REVENUES>                               12,861
<CGS>                                          2,297
<TOTAL-COSTS>                                  17,545
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             8
<INCOME-PRETAX>                                (4,343)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (4,343)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (4,343)
<EPS-BASIC>                                    (0.60)
<EPS-DILUTED>                                  (0.60)


</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission